CTG Pharma

Enabling Therapeutic Application of Chimeric Antigen Receptor T Cells in Solid Tumors

Health Tech & Life Sciences
Non Active, Sep 2022 ceased to operate
Seed Rehovot, Israel Founded 2016
LinkedIn
Last updated 2026-06-18
Total raised
$2.0M
Last: 2018-09
Stage
Seed
Founded
2016
Headcount
1
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences

About

CTG Pharma's solution enables chimeric antigen receptor (CAR) T therapy for HER2-positive solid tumors while mitigating toxicity and on-target off-tumor reactions. CTG Pharma's solutions include a library of 65,000 promoters that enable safer CAR T for the treatment of solid tumors, applicable to any CAR and suitable for a variety of tumor micro-environment conditions. CTG Pharma aims to create a broadly applicable platform to enhance the safety and efficacy of a variety of human CAR T therapies requiring regulation of CAR expression. The platform is composed of a rationally designed library of 65,000 different switches, for minimal immune response in healthy tissues and maximum expression of the CAR specifically in the tumor surroundings. It is a highly sensitive system that integrates unique signals from the solid tumor microenvironment for the regulation of CAR expression. The company's first line of products is HER2-positive cancers.

Funding history · 1 round · $2.0M total

2018-09
$2.0M

Q&A

What is CTG Pharma's primary focus?
CTG Pharma focuses on enabling therapeutic application of Chimeric Antigen Receptor (CAR) T cells in solid tumors, specifically for HER2-positive cancers, while mitigating toxicity.
When was CTG Pharma founded?
CTG Pharma was founded in January 2016.
What is the current status of CTG Pharma?
CTG Pharma is currently inactive, having ceased operations in September 2022.
How much funding has CTG Pharma raised in total?
CTG Pharma has raised a total of $2,000,000.
Which investor participated in CTG Pharma's funding round?
aMoon Fund participated in CTG Pharma's funding round in September 2018.
What is CTG Pharma's employee count?
CTG Pharma has an employee count in the 1-10 range.
Where is CTG Pharma headquartered?
CTG Pharma is headquartered in Rehovot, Center District, Israel.
Who are the co-founders of CTG Pharma?
The co-founders of CTG Pharma are Yoav Ben-Yaacov, Zelig Eshar, and Salomon Stemmer.

Team · 3

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder
Founder · Co-founder & CMO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Tags

bioconvergencecancerpharma-companiespharmaceuticalsgastroenterologywomen-healthoncology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/42122350

Identifiers & details

Founded2016-1
Employees (exact)1
Status reasonNon Active, Sep 2022 ceased to operate